GuanabenzAlternative Names: Guanabenz - The Myelin Repair Foundation/National Institute of Health; MRF 008
Latest Information Update: 15 May 2015
At a glance
- Originator Myelin Repair Foundation; National Institute of Neurological Disorders and Stroke
- Class Antihypertensives; Guanidines
- Mechanism of Action Immunostimulants; Myelin protein stimulants; Nerve growth factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Multiple sclerosis